Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 33-42 , February 2010

Novel therapeutic approaches to the treatment of metastatic breast cancer

  • Yolanda Fernández

      Affiliations

    • Hospital Universitario Central de Asturias, Oviedo, Spain
    • Corresponding Author InformationCorresponding author. Address: Medical Oncology Service, Hospital Universitario Central de Asturias, Calle Celestino Villamil, s/n. 33006-Oviedo, Spain. Tel.: +34 985 108 000; fax: +34 985 108 015.
    • ,
  • Juan Cueva

      Affiliations

    • Complexo Hospitalario Universitario de Santiago, A Coruña, Spain
    • ,
  • Andrés G. Palomo

      Affiliations

    • Hospital de León, León, Spain
    • ,
  • Manuel Ramos

      Affiliations

    • Centro Oncológico Regional, A Coruña, Spain
    • ,
  • Ana de Juan

      Affiliations

    • Hospital Marqués de Valdecilla, Santander, Spain
    • ,
  • Lourdes Calvo

      Affiliations

    • Complexo Hospitalario Universitario Juan Canalejo, A Coruña, Spain
    • ,
  • Jesús García-Mata

      Affiliations

    • Complexo Hospitalario de Ourense, Ourense, Spain
    • ,
  • Paula García-Teijido

      Affiliations

    • Hospital Universitario Central de Asturias, Oviedo, Spain
    • ,
  • Ignacio Peláez

      Affiliations

    • Hospital de Cabueñes, Gijón, Spain
    • ,
  • Laura García-Estévez

      Affiliations

    • Centro Integral Oncológico “Clara Campal”, Madrid, Spain

Received 2 July 2009 ,Revised 30 September 2009 ,Accepted 2 October 2009.

References 

  1. Martin M, Mahillo E, Llombart-Cussac A, et al. The “El Alamo” project (1990–1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clin Transl Oncol. 2006;8:508–518
  2. Chia SK, Speers CH, D’Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–979
  3. Gueth U, Huang DJ, Schoetzau A, Holzgreve W, Wight E. Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials. Oncology. 2009;76:247–253
  4. Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2008;112(Suppl. 1):53–66
  5. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol. 2006;33:S2–S5
  6. Cortázar P, Johnson JR, Justice R, Pazdur R. Metastatic breast cancer (MBC): FDA approval overview. In: ASCO meeting abstracts, vol. 26; 2008. p. 1013.
  7. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–3308
  8. Muss HB, Case LD, Richards F, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991;325:1342–1348
  9. Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998;16:1669–1676
  10. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000;18:3115–24.
  11. Nooij MA, de Haes JC, Beex LV, et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer. 2003;39:614–621
  12. Stockler M, Wilcken N, Coates A. Chemotherapy for advanced breast cancer – how long should it continue?. Breast Cancer Res Treat. 2003;81(Suppl. 1):S49–S52
  13. Alba E, Ruiz-Borrego M, Martin M, et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. In: ASCO meeting abstracts, vol. 25; 2007. p. 1007.
  14. Gennari A, Sormani M, Bruzzi P, et al. A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). In: ASCO meeting abstracts, vol. 26; 2008. p. 1067.
  15. Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 1993;29A:527–531
  16. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987;317:1490–1495
  17. Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24:3912–3918
  18. Gennari A, Sormani M, Bruzzi P, et al. A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts). 2008;26(Suppl. 15):1067
  19. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275–292
  20. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  21. Pronzato P. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. Drugs. 2008;68:139–146
  22. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–3414
  23. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–5217
  24. Bennouna J, Delord JP, Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14:1625–1632
  25. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer. 2006;95:1161–1166
  26. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007;7:919–943
  27. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803
  28. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 2009;20:449–453
  29. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist. 2005;10:363–368
  30. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  31. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer. 2001;37:1366–1371
  32. Llombart-Cussac A, Martin M, Harbeck N, et al. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res. 2007;13:3652–3659
  33. Paridaens R, Dirix L, Dumez H, et al. Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. Clin Breast Cancer. 2007;7:861–866
  34. Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res. 2006;12:832–838
  35. O’Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer. 2005;6:143–149
  36. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 2006;7:317–28.
  37. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer. 2006;94:1610–1614
  38. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;34:45–67
  39. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 Receptor and breast cancer: ten years of targeted Anti-HER-2 therapy and personalized medicine. Oncologist 2009:theoncologist.2008-0230.
  40. Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M, Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist. 2008;13:373–381
  41. Cancello G, Montagna E, D’Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 2008;10:R60
  42. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  43. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother. 2008;9:2583–2601
  44. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122–192
  45. Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol. 2007;64:115–128
  46. Vukelja S, Rugo H, Vogel C, et al. A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. . In: San Antonio breast cancer symposium; 2008 [abstract 33].
  47. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–243
  48. Whenham N, D’Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer. 2008;8:38–49
  49. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343–2346
  50. Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. In: ASCO meeting abstracts, vol. 26; 2008. p. 1026.
  51. Ciardiello F, Troiani T, Caputo F, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer. 2006;94:1604–1609
  52. Cresta S, Perotti A, Merlini L, et al. Combination of paclitaxel and two schedules of gefitinib in patients with metastatic breast cancer. In: ASCO meeting abstracts, vol. 24; 2006. p. 10599.
  53. Cristofanilli M, Valero V, Mangalik A, et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts). 2008;26:1012
  54. Kaur H, Silverman P, Singh D, et al. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts). 2006;24:10623
  55. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007;43:481–489
  56. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15:1452–1459
  57. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26:2999–3005
  58. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  59. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–5552
  60. O’Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. In: ASCO meeting abstracts, vol. 26; 2008. p. 1015.
  61. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 trial. In: San Antonio breast cancer symposium; 2008 [abstract 46].
  62. Burstein H, Sun Y, Tan A, et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. Cancer Res 2009;69(Suppl. 2):73s [abstract 37].
  63. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810–1816
  64. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central cancer treatment group and Mayo clinic trial N0336. J Clin Oncol. 2009;27:11–15
  65. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008;9:1324–1335
  66. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib+lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. In: ASCO meeting abstracts, vol. 26; 2008. p. 1016.
  67. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008;9:658–671
  68. Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). In: ASCO meeting abstracts, vol. 25; 2007. p. 1003.
  69. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186
  70. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049
  71. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25
  72. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5(Suppl 1):37–44
  73. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400
  74. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  75. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62
  76. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  77. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol (Meeting Abstracts). 2008;26:LBA1011
  78. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts). 2009;27:1005
  79. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44:912–920
  80. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 2004;6:219–224
  81. Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. In: ASCO meeting abstracts, vol. 23; 2005. p. 564.
  82. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009:JCO.2008.18.8391.
  83. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007;13:5549s–5555s
  84. Papenfuss K, Cordier SM, Walczak H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med. 2008;12:2566–2585
  85. Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008;19:1379–1386
  86. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–358
  87. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14:1649–1657
  88. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov. 2006;1:397–403
  89. Yang CH, Gonzalez-Angulo AM, Reuben JM, et al. Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006;17:813–817
  90. Engel RH, Brown JA, Von Roenn JH, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest. 2007;25:733–737
  91. Schmid P, Kuhnhardt D, Kiewe P, et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol. 2008;19:871–876
  92. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol. 2008;20:639–649
  93. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008;14:7138–7142
  94. Ramaswamy B, Bhalla K, Cohen B, et al. Phase I–II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703. In: San Antonio breast cancer symposium; 2008 [abstract 404].
  95. Munster PN, Lacevic M, Schmitt M, et al. Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. J Clin Oncol (Meeting Abstracts). 2008;26:3501
  96. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008;8:370–374
  97. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;
  98. O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. In: ASCO meeting abstracts, vol. 27; 2009. p. 3.
  99. 99. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. In: ASCO meeting abstracts, vol. 27; 2009:CRA501.

PII: S0305-7372(09)00142-X

doi: 10.1016/j.ctrv.2009.10.001

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 33-42 , February 2010

Article Tools